Dilated Cardiomyopathy Therapeutic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Dilated Cardiomyopathy Therapeutics Market is segmented by Drug Class (Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers, Beta-blockers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Dilated Cardiomyopathy Therapeutic Market Size

Single User License
Team License
Corporate License
Book before:
Dilated Cardiomyopathy Therapeutic Market Summary
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 3.60 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Dilated Cardiomyopathy Therapeutic Market  Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Dilated Cardiomyopathy Therapeutic Market Analysis

The Dilated Cardiomyopathy Therapeutic Market is projected to register a CAGR of 3.6% during the forecast period.

The COVID-19 pandemic had a significant impact on dilated cardiomyopathy therapeutics market. For instance, according to an article titled 'A case of Dilated Cardiomyopathy in COVID-19,' published in May 2022, comparing cardiac cases in COVID-19 to respiratory cases, cardiac injury was documented in 19.7% to 29.8% of instances. Numerous pathways have contributed to the involvement of the cardiac myocardium in COVID-19, and up to 20-30% of hospitalized patients exhibit this involvement, as seen by high troponin levels. Similarly, in an article titled 'Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis,' published in April 2022, between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19 are thought to experience AM. Hence, this is likely to create more demand for dilated cardiomyopathy therapeutics during the pandemic. However, the postponed treatment procedures and surgeries resumed worldwide, driving the market's growth during the post-pandemic period. Therefore, the high number of heart treatment procedures and operations being performed is expected to boost the growth of the dilated cardiomyopathy therapeutics market during the forecast period.

The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are the increasing prevalence of heart diseases and increasing drug and alcohol abuse. For instance, according to an article published by the National Library of Medicine, in May 2022, around 1.5 million cases of myocarditis occur each year in the entire world. The incidence rate is often calculated as 10 to 20 cases per 100,000 people. Also, according to an article published in 2022, alcohol-induced toxicity leads to non-ischemic dilated cardiomyopathy characterized by loss of contractile function and dilatation of myocardial ventricles. Hence, alcohol use is an important cause of non-ischemic cardiomyopathy and accounts for 10% of all cases of dilated cardiomyopathies. Additionally, according to an article published by Wolters Kluwer, in January 2022, alcohol-induced cardiomyopathy is a type of acquired dilated cardiomyopathy caused by long-term heavy alcohol consumption. It also stated that the prevalence of alcohol-induced cardiomyopathy among patients with heart failure (HF) or dilated cardiomyopathy depends on the threshold alcohol consumption used to identify alcohol-induced cardiomyopathy.

Furthermore, as per an article published by ScienceDirect, in June 2022, substantial proportions of youth surveyed had tried illicit drugs at least once in the countries such as Australia (greater than 40%), Canada (greater than35%), Europe (greater than 23% boys, 17% girls), United States (greater than 40%, more than 25% of 8th graders and nearly half of the 12th graders in the United States reported smoking marijuana daily, and 1 in 7 reported having been a daily marijuana smoker at some time for at least a month. Alcohol use disorder is a common disorder in the United States. The 12-month prevalence of alcohol use disorder is estimated to be 4.6% among 12 to 17-year-olds and 8.5% among adults aged 18 years and older in the United States. Rates of the disorder are greater among adult men (12.4%) than among adult women (4.9%). Twelve-month prevalence of alcohol use disorder among adults decreases in middle age, being greatest among 18 to 29-year-olds (16.2%) and lowest among individuals aged 65 years and older (1.5%). Furthermore, the increasing number of people suffering from cardiac muscle infections, along with drug or alcohol abuse, are also the major factors that help in driving the growth of the market.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However side effects of dilated cardiomyopathy therapeutics are expected to hinder the market growth over the forecast period.

Dilated Cardiomyopathy Therapeutic Market Trends

This section covers the major market trends shaping the Dilated Cardiomyopathy Therapeutic Market according to our research experts:

Angiotensin II receptor blockers is Expected to have a Significant Growth of the Market

Angiotensin II receptor blockers acquire a significant market share, followed by beta-blockers. This is attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. As per an article published by the National Library of Medicine in June 2022, the effects of angiotensin are lessened by angiotensin II receptor blockers (ARBs). High blood pressure is brought on by this protein's tendency to make blood vessels overly tight. ARBs also treat kidney disease and heart failure, as well as reduce the incidence of heart attacks and strokes. These factors are expected to drive and support segmental growth in the market.

Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. For instance, in September 2021, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. had obtained approval in Japan for ENTRESTO 100 mg and 200 mg Tablets for the new indication of hypertension. This approval is Japan's first ARNI for the indication of hypertension. The other driving factors of the segment are also related to the increasing prevalence of heart diseases. According to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, 1 person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020, which is 1 in every 5 deaths. Hence, as the prevalence of heart diseases increases, the growth of the market increases too.

Therefore the above-mentioned factors are expected to drive segmental growth in the market.

Dilated Cardiomyopathy Therapeutic Market  :  Estimated Research Funding for Hypertension (in Million) United States, 2019-2023

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors.

The United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. According to American Heart Association, data updated in July 2022, The most prevalent kind, dilated cardiomyopathy (DCM), primarily affects adults under the age of 50. It affects the bottom and upper chambers of the heart, the ventricles, and the atria. The left ventricle, the heart's primary pumping chamber, is where the disease frequently develops first. The heart muscle starts to widen, stretch, and get thinner. The interior of the chamber therefore grows. The right ventricle is frequently affected before the atria. These factors are expected to promote the growth of the market in the region.

According to National Heart, Lung, and Blood Institute, data updated in March 2022, about 18.2 million American adults have coronary artery disease, making it the most common type of heart disease in the United States. Therefore as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.

Therefore, the above-mentioned factors are expected to drive the market in the region during the forecast period.

Dilated Cardiomyopathy Therapeutic Market - Growth Rate by Region

Dilated Cardiomyopathy Therapeutic Industry Overview

The Dilated Cardiomyopathy Therapeutic Market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research Pvt.ltd., among others.

Dilated Cardiomyopathy Therapeutic Market Leaders

  1. Zensun Shanghai Sci & Tech Co Ltd

  2. Capricor Therapeutics, Inc.

  3. Vericel Corporation

  4. AstraZeneca plc.

  5. Pfizer Inc.

*Disclaimer: Major Players sorted in no particular order

Dilated Cardiomyopathy Therapeutic Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Dilated Cardiomyopathy Therapeutic Market News

  • April 2022: the United States Food and Drug Administration approved Camzyos (mavacamten) capsules to treat adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve exercise capacity and symptoms.
  • September 2022: Rocket pharmaceuticals acquired Renovacor, to extend leadership in AAV-based cardiac gene therapy for significant unmet medical needs in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity comparable to Danon Disease.

Dilated Cardiomyopathy Therapeutic Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Heart Diseases

      2. 4.2.2 Increasing Drugs and Alcohol Abuse

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Dilated Cardiomyopathy Therapeutics

    4. 4.4 Porter Five Forces

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Aldosterone antagonists

      2. 5.1.2 Angiotensin-converting enzyme (ACE) Inhibitors

      3. 5.1.3 Angiotensin II Receptor Blockers

      4. 5.1.4 Beta-blockers

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Zensun Shanghai Sci & Tech Co Ltd

      2. 6.1.2 Capricor Therapeutics, Inc.

      3. 6.1.3 Vericel Corporation

      4. 6.1.4 AstraZeneca plc.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 t2cure GmbH

      7. 6.1.7 MyoKardia and Kasiak Research pvt.ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Dilated Cardiomyopathy Therapeutic Industry Segmentation

As per the scope of the report, dilated cardiomyopathy is a disease of the heart muscle, usually starting in the heart's main pumping chamber (left ventricle). The ventricle stretches and thins (dilates) and can't pump blood as well as a healthy heart can. In general terms, it refers to the abnormality of the heart muscle itself. The Dilated Cardiomyopathy Therapeutic Market is segmented by Drug Class (Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, Beta-blockers), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers
Beta-blockers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Dilated Cardiomyopathy Therapeutic Market Research FAQs

The Dilated Cardiomyopathy Therapeutic Market is projected to register a CAGR of 3.60% during the forecast period (2024-2029)

Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc., Vericel Corporation, AstraZeneca plc. and Pfizer Inc. are the major companies operating in the Dilated Cardiomyopathy Therapeutic Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Dilated Cardiomyopathy Therapeutic Market.

The report covers the Dilated Cardiomyopathy Therapeutic Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Dilated Cardiomyopathy Therapeutic Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Dilated Cardiomyopathy Therapeutic Industry Report

Statistics for the 2024 Dilated Cardiomyopathy Therapeutic market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Dilated Cardiomyopathy Therapeutic analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Dilated Cardiomyopathy Therapeutic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)